# Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

> **NCT02398825** · PHASE2 · TERMINATED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 14 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Chronic Phase
- Adults

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT02398825
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-23
- **Primary completion:** 2020-11-13
- **Final completion:** 2022-12-27
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** low enrollment rate
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398825, "Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02398825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*